Author

Hanna Kortejärvi

Observed names: H Kortejärvi, H. Kortejärvi, Kortejärvi, H., Kortejärvi, Hanna

Institution: University of Helsinki

Observed institutions: University of Helsinki, Helsinki University Hospital, Orion Corporation (Finland)

OpenAlex ID: A5111858259

Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride

2005 · H. Kortejärvi, M. Yliperttula, et al. · Journal of Pharmaceutical Sciences · 103

In Situ Measurement of Solvent-Mediated Phase Transformations During Dissolution Testing

2006 · Jaakko Aaltonen, Paula Heinänen, et al. · Journal of Pharmaceutical Sciences · 99

Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption and elimination rates

2006 · H. Kortejärvi, A. Urtti, et al. · European Journal of Pharmaceutical Sciences · 88

Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines

2007 · Sanna Siissalo, Leena Laitinen, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 56

Patient involvement is essential in identifying drug‐related problems

2018 · Heini Kari, Hanna Kortejärvi, et al. · British Journal of Clinical Pharmacology · 48

Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs

2011 · Paula Lehto, Hanna Kortejärvi, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 41

Challenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier

2013 · Noora Sjöstedt, Hanna Kortejärvi, et al. · Pharmaceutical Research · 30

Effectiveness and cost-effectiveness of a people-centred care model for community-living older people versus usual care ─ A randomised controlled trial

2021 · Heini Kari, Nelli Äijö-Jensen, et al. · Research in Social and Administrative Pharmacy · 28

Development of level A, B and C in vitro–in vivo correlations for modified-release levosimendan capsules

2002 · H. Kortejärvi, J. Mikkola, et al. · International Journal of Pharmaceutics · 28

Prediction of drug dissolution from Toremifene 80 mg tablets by NIR spectroscopy

2020 · Krista Ojala, Mika Myrskyranta, et al. · International Journal of Pharmaceutics · 23

Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs

2009 · H. Kortejärvi, R. Shawahna, et al. · Journal of Pharmaceutical Sciences · 23

Level A in vitro-in vivo Correlation (IVIVC) Model with Bayesian Approach to Formulation Series

2006 · H. Kortejärvi, J. Malkki, et al. · Journal of Pharmaceutical Sciences · 23

Developing an interprofessional people-centred care model for home-living older people with multimorbidities in a primary care health centre: A community-based study

2022 · Heini Kari, Hanna Kortejärvi, et al. · Exploratory Research in Clinical and Social Pharmacy · 15

Pharmacokinetic simulations to explore dissolution criteria of BCS I and III biowaivers with and without MDR-1 efflux transporter

2014 · H. Kortejärvi, J. Malkki, et al. · European Journal of Pharmaceutical Sciences · 13

Modelling and simulation approaches for waiving in vivo pharmacokinetic formulation studies

2008 · Hanna Kortejärvi · Työväentutkimus Vuosikirja · 3

Corrigendum to “Pharmacokinetic simulations to explore dissolution criteria of BCS I and III biowaivers with and without MDR-1 efflux transporter” [European Journal of Pharmaceutical Sciences Volume 61, 30 September 2014, Pages 18–26]

2019 · H. Kortejärvi, J. Malkki, et al. · European Journal of Pharmaceutical Sciences

INT-002 Standardisation of medication counselling material for paediatric solid organ transplant recipients and their families

2018 · A Santamäki, H Kortejärvi, et al. · European Journal of Hospital Pharmacy

Works count: 19

Citation count: 622

H-index: 13

I10-index: 14